Get the Stockscreener App
60.53
1.56%
0.93
After Hours:
60.53
Protagonist Therapeutics Inc stock is traded at $60.53, with a volume of 1.93M.
It is up +1.56% in the last 24 hours and up +12.30% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$59.60
Open:
$59.34
24h Volume:
1.93M
Relative Volume:
2.38
Market Cap:
$3.77B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
23.10
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
+2.51%
1M Performance:
+12.30%
6M Performance:
+57.43%
1Y Performance:
+44.05%
1-Day Range:
$58.03
$61.04
1-Week Range:
$57.45
$61.04
52-Week Range:
$33.31
$61.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
60.53 | 3.71B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics’ PN-881 Study: A Closer Look at Market Implications - TipRanks
Applying Wyckoff theory to Protagonist Therapeutics Inc. stock2025 Biggest Moves & Safe Swing Trade Setups - Newser
Is Protagonist Therapeutics Inc. a cyclical or defensive stock2025 Risk Factors & Real-Time Sentiment Analysis - خودرو بانک
What is Protagonist Therapeutics Inc. s revenue forecastJuly 2025 Short Interest & High Return Trade Guides - خودرو بانک
Aug Levels: Is Protagonist Therapeutics Inc. in a bullish channelEarnings Recap Report & Weekly High Return Stock Opportunities - classian.co.kr
Institutional scanner results for Protagonist Therapeutics Inc.July 2025 Outlook & Community Supported Trade Ideas - Newser
Live market analysis of Protagonist Therapeutics Inc.Bull Run & Fast Momentum Entry Tips - Newser
What’s the recovery path for long term holders of Protagonist Therapeutics Inc.July 2025 Weekly Recap & High Accuracy Investment Signals - Newser
Will Protagonist Therapeutics Inc. benefit from geopolitical trendsMarket Sentiment Report & Real-Time Volume Spike Alerts - خودرو بانک
Can Protagonist Therapeutics Inc. expand into new markets2025 Fundamental Recap & Reliable Price Breakout Signals - خودرو بانک
Is Protagonist Therapeutics Inc. affected by consumer sentiment2025 Volume Leaders & AI Driven Stock Reports - خودرو بانک
Custom watchlist performance reports with Protagonist Therapeutics Inc.July 2025 Review & Reliable Momentum Entry Alerts - Newser
Can volume confirm reversal in Protagonist Therapeutics Inc.2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Will Protagonist Therapeutics Inc. benefit from rate cutsCPI Data & Technical Pattern Recognition Alerts - خودرو بانک
Is Protagonist Therapeutics Inc. vulnerable to short sellers2025 EndofYear Setup & Entry Point Confirmation Signals - خودرو بانک
Is Protagonist Therapeutics Inc. in a bullish channel2025 Support & Resistance & Consistent Profit Trading Strategies - خودرو بانک
How is Protagonist Therapeutics Inc. managing supply chain issues2025 Year in Review & Verified Momentum Stock Ideas - خودرو بانک
Using Ichimoku Cloud for Protagonist Therapeutics Inc. technicalsMarket Risk Report & Daily Stock Momentum Reports - Newser
Applying big data sentiment scoring on Protagonist Therapeutics Inc.Market Risk Analysis & Weekly High Potential Stock Alerts - Newser
Can Protagonist Therapeutics Inc. continue delivering strong returns2025 Pullback Review & AI Powered Buy/Sell Recommendations - khodrobank.com
What momentum shifts mean for Protagonist Therapeutics Inc.Weekly Trade Summary & Daily Volume Surge Signals - Newser
Comparing Protagonist Therapeutics Inc. in custom built stock radarsTrade Risk Report & Detailed Earnings Play Alerts - Newser
Will Protagonist Therapeutics Inc. stock go up soon2025 Support & Resistance & Risk Controlled Swing Alerts - Newser
Technical analysis overview for Protagonist Therapeutics Inc. stock2025 Price Momentum & Reliable Entry Point Trade Alerts - Newser
Published on: 2025-09-04 00:44:39 - Newser
What MACD signals say about Protagonist Therapeutics Inc.Earnings Overview Report & Reliable Entry Point Alerts - Newser
How to build a custom watchlist for Protagonist Therapeutics Inc.Portfolio Gains Summary & Accurate Trade Setup Notifications - Newser
Transcript : Protagonist Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 09 - MarketScreener
Real time social sentiment graph for Protagonist Therapeutics Inc.Earnings Overview Summary & Community Consensus Picks - Newser
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Democrat and Chronicle
What to do if you’re stuck in Protagonist Therapeutics Inc.2025 Retail Activity & Safe Capital Growth Tips - Newser
Protagonist Therapeutics Inc. stock trendline breakdownWeekly Volume Report & Step-by-Step Swing Trade Plans - Newser
Can Protagonist Therapeutics Inc. stock outperform in a bear marketJuly 2025 Volume & AI Driven Price Predictions - خودرو بانک
Can technical indicators confirm Protagonist Therapeutics Inc.’s reversal2025 Macro Impact & Fast Entry Momentum Alerts - Newser
Has Protagonist Therapeutics Inc. formed a bullish divergencePortfolio Return Summary & Precise Buy Zone Tips - Newser
Buyback Watch: Is Protagonist Therapeutics Inc. being accumulated by smart money2025 Historical Comparison & Fast Entry and Exit Trade Plans - خودرو بانک
Combining machine learning predictions for Protagonist Therapeutics Inc.2025 Earnings Impact & Fast Moving Stock Watchlists - Newser
Protagonist Therapeutics Inc. recovery potential after sell offQuarterly Earnings Summary & High Yield Equity Trading Tips - Newser
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):